Does Betaseron Slow Disability in Secondary Progressive MS?
Betaseron (interferon beta-1b) shows limited effectiveness for secondary progressive multiple sclerosis (SPMS), particularly when relapses are absent. In the pivotal European/Canadian trial (432 patients, 3 years), it reduced confirmed disability progression by 18% (hazard ratio 0.82, p=0.0007) compared to placebo, but only in patients without recent relapses. No benefit appeared in SPMS with active relapses.[1][2]
The FDA approved Betaseron for SPMS without activity in 2003 based on this data, but it lacks approval for relapsing SPMS forms.[3]
How Does This Compare to Trials for Relapsing MS?
Betaseron works better in relapsing-remitting MS (RRMS), reducing relapses by 30-34% and MRI lesions.[1] For SPMS, the benefit is smaller and relapse-independent, reflecting slower disease mechanisms like neurodegeneration over inflammation.[4]
| MS Type | Key Trial Outcome | Relapse Reduction | Disability Progression Delay |
|---------|------------------|-------------------|------------------------------|
| RRMS | 30-34% fewer relapses [1] | Yes | Moderate |
| SPMS (no relapses) | 18% less progression [2] | No | Limited |
| SPMS (with relapses) | No benefit [2] | Minimal | None |
What Do Recent Studies and Guidelines Say?
Long-term data (e.g., 5-year extensions) confirm modest SPMS benefits, but meta-analyses question clinical meaningfulness due to small effect sizes.[5] ECTRIMS/EAN 2021 guidelines list it as an option for early SPMS without activity, but recommend higher-efficacy drugs like ocrelizumab or siponimod for active SPMS.[6] No new phase 3 trials since 2003 support expanded use.
Common Patient Concerns and Side Effects
Patients report flu-like symptoms (fever, chills in 60%), injection-site reactions (50-85%), liver enzyme elevations (10%), and depression risk.[3] In SPMS trials, 25% discontinued due to side effects vs. 18% on placebo.[2] Effectiveness wanes over 2-3 years for many, prompting switches to oral therapies.
Alternatives for SPMS Treatment
- Active SPMS: Ocrelizumab (38% progression delay, RMS trial extension)[7]; siponimod (21% delay, EXPAND trial)[8].
- Non-active SPMS: Mitoxantrone (historic, toxic); off-label cladribine or HSCT for select cases.
- Emerging: BTK inhibitors (e.g., evobrutinib, phase 3 ongoing).
Consult neurologists; no generics for Betaseron (patent expired 2007, but Bayer exclusivity ended 2013).[9]
Sources
[1]: Betaseron Prescribing Information
[2]: Lancet 1998;352:1491-7
[3]: FDA Approval History
[4]: NEJM 1993;329:1764-9 (RRMS benchmark)
[5]: Cochrane Review 2017
[6]: ECTRIMS/EAN Guidelines 2021
[7]: Ocrevus RMS Extension
[8]: Siponimod EXPAND Trial
[9]: DrugPatentWatch: Betaseron